Last edition
News about "SynaptixBio Advances Rare Disease Therapy with Bre"
SynaptixBio Advances Rare Disease Therapy with Breakthrough ASO Candidate
Oxford-based biotech company SynaptixBio has announced a major breakthrough in its quest to treat H-ABC, a rare, fatal, and currently incurable neurodegenerative disease. The company has identified its lead drug candidate, SB H-19642, which is now being prepared for clinical trials.
SynaptixBio Advances Rare Disease Therapy With Bre | 21/06/2025 | By Darshana | 193
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members